1364. Association Between Tixagevimab/Cilgavimab Administration and Self-Reported SARS-CoV-2 Infection During the Omicron Surge

BACKGROUND: Immunocompromised patients are at high risk for COVID-19 morbidity and mortality. While findings from the PROVENT study led to emergency use authorization of tixagevimab/cilgavimab (TC) for pre-exposure prophylaxis, less is known of its protection in vaccinated immunocompromised patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathew, Daniya S, Saunders-Hao, Patricia, Jain, Sumeet, Ball, Trever, Abel-Bey, Amparo, Bowman, Keisha, Gandhi, Shivanthidevi, Gautam-Goyal, Pranisha, Brown, Zenobia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678761/
http://dx.doi.org/10.1093/ofid/ofad500.1201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678761/
http://dx.doi.org/10.1093/ofid/ofad500.1201

Ejemplares similares